Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Dermatol Ther (Heidelb) · 2026 · PMC13237397 · PMID 42143206

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

nominally significantP ≤ 0.01actually significant

Nominally significant differences versus placebo were generally observed from week 2 ( P ≤ 0.01) and from week 4 onward ( P < 0.001) for both zasocitinib doses across all domains.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.